TTP 22

Cat. No.:	HY-15479
CAS No.:	329907-28-0
Molecular Formula:	$C_{16}H_{14}N_2O_2S_2$
Molecular Weight:	330.42
Target:	Casein Kinase
Pathway:	Cell Cycle/DNA Damage; Stem Cell/Wnt
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 51 mg/mL (154.35 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	3.0265 mL	15.1323 mL	30.2645 mL
5 mM	0.6053 mL	3.0265 mL	6.0529 mL
10 mM	0.3026 mL	1.5132 mL	3.0265 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (7.57 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

TTP 22 is a potent CK2 inhibitor, with an IC_{50} of 100 nM and a K_i of 40 nM.

IC_{50} & Target

CK2
100 nM (IC_{50})

In Vitro

TTP 22 is a potent CK2 inhibitor, with an IC_{50} of 100 nM and a K_i of 40 nM. TTP 22 shows no effect on other kianses such as Jnk3, Rock1, Tie2, Ask1, Met and FGFR1 at 10 μM[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Patent. US20200368248A1.
- Patent. US20180263995A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Golub AG, et al. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Eur J Med Chem. 2011 Mar;46(3):870-6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA